The brothers RAF.
Targeted molecular therapies for cancer treatment have shown promise, but also have limitations. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies with clinical effectiveness against one melanoma subtype may have adverse clinical effects in another.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Lawrence N
LN
Kwong
Lynda
L
Chin
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D045744:Cell Line, Tumor; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D018631:ras Proteins / Q000378:metabolism
D000970:Antineoplastic Agents; D048493:Proto-Oncogene Proteins B-raf; D019908:Proto-Oncogene Proteins c-raf; D018631:ras Proteins